CN101732440A - Raspberry extract and raspberry element obtain by separation thereof and application thereof - Google Patents
Raspberry extract and raspberry element obtain by separation thereof and application thereof Download PDFInfo
- Publication number
- CN101732440A CN101732440A CN200910201133A CN200910201133A CN101732440A CN 101732440 A CN101732440 A CN 101732440A CN 200910201133 A CN200910201133 A CN 200910201133A CN 200910201133 A CN200910201133 A CN 200910201133A CN 101732440 A CN101732440 A CN 101732440A
- Authority
- CN
- China
- Prior art keywords
- fructus rubi
- extract
- raspberry
- group
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to medical technical field, relating to raspberry extract extracted from Rubus chingii Hu and raspberry element obtained from separating the raspberry extract and the application of the two in preparing medicines for treating and preventing chronic nephritis, kidney-yang deficiency and osteoporosis. The raspberry element has the following chemical structural formula. The raspberry extract and the raspberry element have activity of treating and preventing chronic nephritis, kidney-yang deficiency and osteoporosis, thereby being capable of preparing medicines for treating and preventing chronic nephritis, kidney-yang deficiency or osteoporosis.
Description
Technical field
The present invention relates to medical technical field, be the Fructus Rubi extract that from Fructus Rubi (Rubus chingii Hu), extracts and therefrom separate plain and their application in preparation treatment and prevention chronic nephritis, insufficiency of kidney-YANG or medicine for treating osteoporosis of the Fructus Rubi that obtains.
Background technology
Fructus Rubi (Fructus rubi) is the dry almost ripe fruit of Rosaceae rubus Fructus Rubi (Rubus chingii Hu).Sweet, sour, temperature.Return kidney, urinary bladder channel.Kidney tonifying, controlling nocturnal emission with astringent drugs, reducing urination.Be used for enuresis due to deficiency of the kidney, frequent micturition, impotence and premature ejaculation, diseases such as emission and spermatorrhea.Fructus Rubi is abundant in china natural resources, mainly is distributed in ground such as Zhejiang, Jiangsu, Anhui, Jiangxi, Fujian, Guangxi, in that " Chinese pharmacopoeia is recorded.In recent years, both at home and abroad to the existing certain research of Fructus Rubi, to German army's report, Fructus Rubi extract has certain warming the kidney to activate YANG effect (ACAD J GCP 2002.18 (3): 217-218), but not mentioned its active component.Up to the present, do not see that Fructus Rubi extract has the chronic nephritis of control, insufficiency of kidney-YANG or osteoporotic report yet.
Summary of the invention
The invention provides a kind of Fructus Rubi extract and reach noval chemical compound-Fructus Rubi element that separation obtains from Fructus Rubi extract with the chronic nephritis of preventing and treating, osteoporosis activity.The chemical structural formula of Fructus Rubi element is:
The present invention studies show that the Fructus Rubi element is the active component of Fructus Rubi extract, has the activity of the chronic nephritis of preventing and treating, osteoporosis and insufficiency of kidney-YANG.
The preparation method of Fructus Rubi extract of the present invention and Fructus Rubi element is as follows:
1. preparation Fructus Rubi extract
With percolation extraction or the immersion extraction routinely of 0-95% ethanol water, preferably use the 50-80% ethanol water to extract the Fructus Rubi dry fruit, the best is 70% ethanol water, and extracting solution is evaporated to the pure extractum of distinguishing the flavor of of nothing, gets Fructus Rubi extract;
2. prepare the plain semifinished product of Fructus Rubi
With using petroleum ether, dichloromethane extraction successively behind the above-mentioned Fructus Rubi extract dilute with water, abandon extract, use the water saturation n-butanol extraction then, with the butanol extraction liquid concentrating under reduced pressure, get the plain semifinished product of Fructus Rubi;
3. separation and Extraction Fructus Rubi element
With the plain semifinished product water of above-mentioned Fructus Rubi suspendible, last macroporous resin D101 distinguishes water, 30%, 60% and 95% ethanol water eluting successively, collect 30% ethanol elution, concentrating under reduced pressure becomes the extractum shape and uses dissolve with methanol, mixes sample with silica gel H (60 types, Qingdao Haiyang Chemical Industry Group Corp.), last silica gel H chromatographic column, with chloroform-methanol (30: 1-1: 1) solvent system eluting, collect 5: 1 eluent of chloroform-methanol, and concentrate, with getting yellow powder after the washed with methanol, also be the Fructus Rubi element.
Through zoopery, Fructus Rubi extract of the present invention and Fructus Rubi element have the chronic nephritis of control, insufficiency of kidney-YANG and osteoporotic activity, therefore can be used for preparation and prevent and treat chronic nephritis, insufficiency of kidney-YANG and osteoporotic medicine.
The plain compounds process for production thereof of extract of the present invention and Fructus Rubi is simple, with low cost, and the present invention provides a kind of new medicament sources for preventing and treating chronic nephritis, insufficiency of kidney-YANG and osteoporosis.
The specific embodiment:
Now in conjunction with the embodiments the present invention is described in detail.
Used Fructus Rubi is the Fructus Rubi that in JIUYUE, 2007 is collected in Zhejiang Hangzhou.
Embodiment 1. preparation Fructus Rubi extracts
Fructus Rubi dry fruit 50kg, with aqueous solution percolation extraction routinely, extracting solution is evaporated to the extractum that does not have the alcohol flavor, gets Fructus Rubi extract 12.6kg.
Embodiment 2. preparation Fructus Rubi extracts
Fructus Rubi dry fruit 50kg, with the percolation extraction routinely of 95% solution, extracting solution is evaporated to the extractum that does not have the alcohol flavor, gets Fructus Rubi extract 2.4kg.
Embodiment 3. preparation Fructus Rubi extracts
Fructus Rubi dry fruit 50kg, with the percolation extraction routinely of 70% ethanol water, extracting solution is evaporated to the extractum that does not have the alcohol flavor, gets Fructus Rubi extract 6.5kg.
Embodiment 4. usefulness Fructus Rubi extracts prepare the Fructus Rubi element
1. prepare the plain semifinished product of Fructus Rubi
It is 50L that the Fructus Rubi extract of embodiment 3 preparation is diluted with water to volume, extract respectively 3 times with the 50L petroleum ether earlier, abandon extract, reuse 50L dichloromethane extraction 3 times is abandoned extract, uses the water saturation n-butanol extraction then 3 times, each 50L, merge butanol extraction liquid, concentrating under reduced pressure gets the plain semifinished product of Fructus Rubi.
2. separation and Extraction Fructus Rubi element
With the plain semifinished product water of above-mentioned Fructus Rubi suspendible, last macroporous resin D101, water, 30%, 60% and 95% ethanol water eluting successively, collect 30% ethanol elution, concentrating under reduced pressure becomes the extractum shape and uses dissolve with methanol, mixes sample with silica gel H (60 types, Qingdao Haiyang Chemical Industry Group Corp.), last silica gel H chromatographic column, with chloroform-methanol (30: 1-1: 1) solvent system eluting, collect 5: 1 eluent of chloroform-methanol, and concentrate, with getting yellow powder after the washed with methanol, also be the Fructus Rubi element.
Structure is identified:
Yellow powder, m.p.:267-269 ℃, ESI-MS:m/z 247[M-H]
-, determining that compound molecular weight is 248, HR-MS shows that molecular formula is: C
12H
8O
6UV(EtOH)：λmax(ε)＝364(10143)，299(28317)，200(17918)。IR(KBr)：v
O-H＝3404cm
-1，v
C＝O＝1684cm
-1，v
C＝C＝1599cm
-1，v
CH2＝1392cm
-1，v
C-O＝1305cm
-1。
1H-NMR (400MHz, δ, pyridine-d5) in,
1(2H, m), (2H m), shows-CH in δ=3.5 in HNMR signal δ=2.5
2-CH
2-, (1H s), is shown as the H on two keys in δ=8.0.
13Signal δ=195.5 among the C-NMR and δ=160.5 show a α, the existence of alpha, beta-unsaturated ketone and alpha, beta-unsaturated esters.From
13During composing, C-NMR spectrum and DEPT contain 9 season C, 1-CH, 2-CH as can be known in this chemical compound
2,
13110-150 has 6 peaks among the C-NMR, shows that 6 peaks are season C in the DEPT spectrum, and expression has 6 substituted benzene rings to exist.
Comprehensive above information can infer that this chemical compound is a phenyl ring, Yi Bian connect a hexa-atomic lactonic ring, Yi Bian connect five yuan of ketone rings, two C are replaced by OH in addition.
Can further belong to the hydrocarbon of this chemical compound according to the HMQC spectrum.
In the HMQC spectrum, the corresponding δ of the secondary C of δ=23.8=3.5 (2H, H m), the corresponding δ of the secondary C of δ=33.0=2.5 (2H, H m), the corresponding δ of the season C of δ=108.0=8.0 (1H, H s).Among the HMBC, the H of δ=8.0 and δ=160.5,140.1,144.2,149.3,113.2 C is relevant, illustrates that two keys link to each other with phenyl ring with ester bond respectively, the H of δ=2.5 and δ=141.1,195.5,23.8 C is relevant, and this CH is described
2Link to each other with the ketone carbonyl, the H of δ=3.5 and δ=141.1,145.0,195.5,23.8 C is relevant, and two CH are described
2Link to each other, and the latter is connected on the phenyl ring.Each model ownership is as shown in table 1.
Comprehensive above the analysis determined the complete structure of this chemical compound, called after Fructus Rubi element, and its structural formula is:
Table 1. Fructus Rubi element
1H,
13The C-NMR data (400MHz, δ, pyridine-d5)
| The position | ??C | ??DEPT | ??H | ??HMBC |
| ??1 | ||||
| ??2 | ??160.5 | |||
| ??3 | ??140.1 | |||
| ??4 | ??108.0 | ??CH | ??8.0(1H，s) | ??2，3，5，9，10 |
| ??5 | ??144.2 | |||
| ??6 | ??115.5 | |||
| ??7 | ??141.1 |
| The position | ??C | ??DEPT | ??H | ??HMBC |
| ??8 | ??145.0 | |||
| ??9 | ??149.3 | |||
| ??10 | ??113.2 | |||
| ??11 | ??195.5 | |||
| ??12 | ??33.0 | ??CH 2 | ??2.5(2H，m) | ??7，11，13 |
| ??13 | ??23.8 | ??CH 2 | ??3.5(2H，m) | ??7，8，11 |
Pharmacology, effect experiment
The pharmacology of Fructus Rubi extract of the present invention and Fructus Rubi element or pharmacodynamic experiment method are basic identical, and existing details are as follows:
One, Fructus Rubi extract and Fructus Rubi element are to the preventive and therapeutic effect of rat passive-type Heymann nephritis
Passive-type Heymarm nephritis is the classical model of the human membranous nephropathy of research, is marked feature [Chinese Journal of Nephrology .1999.15 (3): 158] with a large amount of albuminuria.Therefore, the present invention's usefulness Heymann nephritis scale-model investigation Fructus Rubi extract and Fructus Rubi element are to the preventive and therapeutic effect of nephritis.
1, test material
1.1, experimental apparatus
BCA protein detection kit (Pierce company, the U.S.), ReverTra DashTM test kit (Toyobo company, Japan).
1.2, for test agent:
Fructus Rubi extract (embodiment 3 preparations)
Fructus Rubi element (embodiment 4 preparations, purity all is not less than 93.2%, down together);
Dexamethasone (Hebei Ji Heng pharmaceutcal corporation, Ltd)
Facing the time spent uses 0.5% sodium carboxymethyl cellulose (CMCNa) to be mixed respectively Fructus Rubi extract, Fructus Rubi element and dexamethasone to make respective concentration.
2, experimental animal
Strain: Wistar rat
Sex: male
Body weight: 175～200 grams
Source: Chinese Academy of Sciences's Shanghai animal center (down together)
The animal quality certification: Shanghai is moving closes the card word No. 005
Raise: constant-temperature purification ventilation Animal House, ad lib and drinking-water, 25 ± 2 ℃.
3, test method
3.1 prepare anti-FX1A serum
1) preparation FX1A antigen
Normal male Wistar rat, the skin of sterilizing behind the etherization, cut off splanchnocoel, with aseptic cold saline lavation kidney, separating renal cortex then weighs, add an amount of normal saline after cortex fully ground to form homogenate, filter with 80 orders, 100 orders and 220 eye mesh screens successively, collect last filtrate, filtrate is centrifugal with 1600r/min20min, get supernatant, repeated centrifugation is once got supernatant, abandons supernatant with 10000r/min 30min after centrifugal again, precipitate is washed 3 times with distilled water, and the gained precipitate is a FXA1A antigen.
2) the anti-FX1A serum of preparation
With the FXA1A antigen of above-mentioned preparation and equal-volume Freund's complete adjuvant fully emulsified after, 2 weeks are through subcutaneous immune large ear rabbit at interval, get serum after the immunity 6 times altogether.Measure with immune directional diffusion and indirect immunofluorescence and to tire, reach 1: 32 respectively and 1: 2000 for qualified.Carotid artery is got blood, separation of serum, and it is anti-FX1A serum ,-20 ℃ are standby, deactivation before using.
3.2, the foundation of passive-type Heymann nephritis model and animal grouping
75 of extracting male Wistar rats, their 24h urine protein is all less than 10mg.Be equally divided into 5 groups at random: positive controls, Fructus Rubi extract group, the plain group of Fructus Rubi, model control group (being called for short model group, down together) and blank group (being called for short blank group, down together).The disposable tail vein injection saline 5ml/kg of blank group; All the other are respectively organized the anti-FX1A serum of the disposable tail vein injection of rat 5ml/kg and carry out modeling, played per os gastric infusion every day (dosage calculates with per kilogram of body weight respectively) same day in modeling, totally 4 weeks, dosage be respectively positive controls (dexamethasone, 0.1mg/kg/d); Fructus Rubi extract group (30g/kg/d); The plain group of Fructus Rubi (10mg/kg/d); Sodium carboxymethyl cellulose (CMCNa) the suspension 5mg/kg/d of model group and every the rat oral perfusion 0.5% every day of blank group.
3.3, observation index
Urine protein quantitation adopts BCA (bicinchoninincacid) method, and 5 groups all begin to put into metabolic cage respectively the 2nd and the 4th weekend in week in modeling, collect the 24h urine.(x ± SD) expression, each group compares with model group respectively measurement data, adopts bilateral two sample t check carrying out statistical analysis with mean ± standard deviation.The results are shown in Table 2.
Table 2. rat urine albumen amount statistical table
Compare with model group: * * P＜0.01
By table 2 as seen, the plain urine albumen amount of Fructus Rubi extract and Fructus Rubi is starkly lower than model group (P＜0.05), approaches positive controls, illustrates that Fructus Rubi extract of the present invention and Fructus Rubi element have significant curative effect to passive-type Heymann nephritis.
Two, Fructus Rubi extract, Fructus Rubi element are to the preventive and therapeutic effect of the inductive mice insufficiency of kidney-YANG of hydrocortisone
The present invention has selected the inductive mice insufficiency of kidney-YANG of hydrocortisone model for use, and this model is classical, commonly used insufficiency of kidney-YANG model.
1, test material
1.1, the modeling medicine
Title: hydrocortisone
Source: Tianjin Biochemical Pharmaceutical Factory
Content: 50mg/ bottle
Character: injection powder pin
Preparation: be made into 3.57mg/ml with normal saline.
1.2, for test agent:
Fructus Rubi extract, Fructus Rubi element are the same; Methyltestosterone tablets (Shanghai Sine Kangjie Pharmaceutical Co., Ltd.); JINGUI SHENQI WAN (Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory).
Obtain solution: facing the time spent is dissolved in the suspension that respective concentration is made in 1% tragakanta with Fructus Rubi extract, Fructus Rubi element;
Methyltestosterone: the suspension of making 30mg/ml with 1% tragakanta;
JINGUI SHENQI WAN: the suspension of making 150mg/kg with 1% tragakanta.
2, experimental animal
Strain: ICR mice
Age: 6 ages in week
Rank: cleaning level
Sex: male
Body weight: 25g ± 2g
Source: Shanghai Si Laike laboratory animal responsibility company limited
The animal quality certification number: SCXK (Shanghai) 2007-0005
Raise: cleaning level Animal House, ad lib and water inlet, temperature: 25 ± 2 ℃, humidity: 40-60%, artificial lighting's simulation changes round the clock.
3, test method
64 of male ICR mouses adapt to 3 days under experiment condition.Random packet, 8 every group.Remove blank group every mouse peritoneal injection every day 0.2ml continuous normal saline injection 10 beyond the highest heavens, all the other respectively organize the modeling of every mouse peritoneal injection every day 0.2ml hydrocortisone solution, irritate the medicinal liquid that preparation is stated on the Weishang simultaneously respectively, dosage is: Fructus Rubi extract low dose group 10g/kg; Fructus Rubi extract high dose group 30g/kg; The plain low dose group 5mg/kg of Fructus Rubi; The plain high dose group 10mg/kg of Fructus Rubi; Methyltestosterone group 0.65g/kg; JINGUI SHENQI WAN group 6g/kg; Model group and blank group are irritated stomach 0.5ml 1% tragakanta respectively, and inject hydrocortisone solution continuously 10 days.Administration the 13rd day, each is organized mice and weighs, and eye socket is got blood, puts to death mice then.Win testis, the kidney of mice, weigh.Mouse blood was placed after 2 hours, and is centrifugal, gets serum, is placed in-20 ℃ of refrigerators, to be measured.
Each organizes mouse kidney and testicular weight zero difference, and blood serum sample uses the testosterone chemical luminescence reagent kit, according to the operation instruction operation, measures serum testosterone concentration.Calculate the meansigma methods and the standard deviation (n=8) of every group of mice body weight and testosterone concentration, experimental data represents that with x ± SD each group compares with model group respectively, adopts bilateral two sample t check to carry out statistical analysis, the results are shown in Table 3.
The horizontal statistical table of body weight of table 3 mice and testosterone concentration
Compare with model group: * P＜0.05, * * P＜0.01
By table 3 as seen, model group mice body weight is starkly lower than blank group, and the blank group of blood testosterone levels has the difference (P＜0.01) of highly significant.The plain group of Fructus Rubi extract of the present invention and Fructus Rubi, body weight is near blank group and methyltestosterone and JINGUI SHENQI WAN group; Blood testosterone levels and methyltestosterone and JINGUI SHENQI WAN winding are near, the plain high dose group of Fructus Rubi extract and Fructus Rubi particularly, the blood testosterone levels is basic to maintain an equal level with blank group and methyltestosterone and JINGUI SHENQI WAN group, has compared significant difference (P＜0.01) with model group.The result shows that Fructus Rubi extract of the present invention and Fructus Rubi element have tangible preventive and therapeutic effect to the mice insufficiency of kidney-YANG.
Three, Fructus Rubi extract and Fructus Rubi element cause the osteoporotic therapeutical effect of mice to retinoic acid
Effect for the osteoporosis of studying Fructus Rubi extract and Fructus Rubi element, this experiment adopts retinoic acid to cause osteoporotic animal model, because all-trans-retinoic acid is a kind of immunosuppressant, it has the bone of inhibition and synthesizes the effect of grade, so be commonly used to set up the animal osteoporosis model.
1, test material
1.1, experimental apparatus
AE240 electronic balance (prunus mume (sieb.) sieb.et zucc. Teller-Tuo benefit instrument company).
1.2, for test agent:
Fructus Rubi extract and Fructus Rubi element are the same; All-trans-retinoic acid (day Industrial Co., Ltd. in the Henan); Alendronate sodium (North China drugmaker).
Preparation: facing the time spent is dissolved in Fructus Rubi extract, Fructus Rubi element, all-trans-retinoic acid and Alendronate sodium respectively in 0.5% sodium carboxymethyl cellulose (CMCNa) suspension stand-by.
Hydroxyproline (HOP) detection kit (bio-engineering research institute is built up in Nanjing).
2, experimental animal
Strain: Kunming mouse
Sex: male
Body weight: 33 ± 4 grams
Source: Chinese Academy of Sciences's Shanghai animal center
The animal quality certification: Shanghai is moving closes the card word No. 005
Raise: constant-temperature purification ventilation Animal House, ad lib and drinking-water, 25 ± 2 ℃.
3, test method
40 of Kunming mouses are divided into 4 groups at random, 10 every group: be respectively blank group, model group, Fructus Rubi extract group (30g/kg), the plain group of Fructus Rubi (10mg/kg).Except that the blank group, all the other each group is all used all-trans-retinoic acid (105mg/kg) modeling, every morning the gastric infusion retinoic acid, irritate the medicine that stomach gives the mice corresponding dosage afternoon, model group and blank group are irritated sodium carboxymethyl cellulose (CMCNa) suspension of stomach 0.5%, totally 14 days respectively.Weigh weekend once weekly in the experimentation, put to death animal on the 15th day, and get right femur and use for measuring.
After mouse femur cuts open and gets, reject the soft tissue adhere to, dry to constant weight through 80 ℃, and be determined as follows:
(1) key remeasurement: use electronic balance weighing, get key weight;
(2) bone length base bone transverse diameter is measured: with slide gauge femur length and transverse diameter are measured;
(x ± SD) expression, measurement data compares between organizing with the t check experimental result with mean ± standard deviation.
The results are shown in Table 4.
Body weight of table 4 mice and bone index statistical table
Compare with model group: * P＜0.05, * * P＜0.01; Compare with model group: #P＜0.05, ##P＜0.01
By table 4 as seen, right femur dry weight of model group mice and the horizontal minor axis of right femur are all significantly less than the blank group, and the plain group of Fructus Rubi extract or Fructus Rubi all is significantly higher than model group (P＜0.05, P＜0.01).Illustrate that Fructus Rubi extract or Fructus Rubi element have preventive and therapeutic effect to osteoporosis.
Claims (7)
1. Fructus Rubi extract, preparation method is:
With Fructus Rubi dry fruit 0-95% ethanol water percolation extraction or immersion extraction routinely, extracting solution is evaporated to does not have pure extractum of distinguishing the flavor of, and gets Fructus Rubi extract.
2. by the described Fructus Rubi extract of claim 1, it is characterized in that Fructus Rubi dry fruit 50-80% ethanol water percolation extraction or immersion extraction routinely.
3. by the described Fructus Rubi extract of claim 2, it is characterized in that with the Fructus Rubi dry fruit with 70% ethanol water routinely percolation extract or soak extraction.
4. by claim 1 or 2 or 3 described Fructus Rubi extracts, it is characterized in that it contains the Fructus Rubi element.
5. the plain chemical compound of a Fructus Rubi, chemical structural formula is:
6. claim 1 or 2 or 3 described Fructus Rubi extracts are prevented and treated application in chronic nephritis or the medicine for treating osteoporosis in preparation.
7. the described Fructus Rubi element of claim 4 is prevented and treated application in chronic nephritis, insufficiency of kidney-YANG or the medicine for treating osteoporosis in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102011334A CN101732440B (en) | 2009-12-15 | 2009-12-15 | Raspberry extract and raspberry element obtain by separation thereof and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102011334A CN101732440B (en) | 2009-12-15 | 2009-12-15 | Raspberry extract and raspberry element obtain by separation thereof and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101732440A true CN101732440A (en) | 2010-06-16 |
| CN101732440B CN101732440B (en) | 2012-05-30 |
Family
ID=42456808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102011334A Expired - Fee Related CN101732440B (en) | 2009-12-15 | 2009-12-15 | Raspberry extract and raspberry element obtain by separation thereof and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732440B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102987548A (en) * | 2012-12-05 | 2013-03-27 | 陕西中烟工业有限责任公司 | Plant extract capable of reducing harmful substances in cigarette and preparation method thereof |
| CN103284143A (en) * | 2012-03-31 | 2013-09-11 | 蔡晓鹏 | Rubus chingii decoction piece and preparation method thereof |
| CN103316024A (en) * | 2013-06-18 | 2013-09-25 | 中国人民解放军第二军医大学 | Application of labdane diterpene glycoside compounds in rubus chingii Hu as medicine |
| CN103623082A (en) * | 2013-11-29 | 2014-03-12 | 江西中医药大学 | Raspberry extract and application thereof |
| CN107353273A (en) * | 2017-07-17 | 2017-11-17 | 湖南楚宏生物科技有限公司 | The method that cyanidenon and Rubus corchorifolius element are extracted from Rubus corchorifolius |
-
2009
- 2009-12-15 CN CN2009102011334A patent/CN101732440B/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103284143A (en) * | 2012-03-31 | 2013-09-11 | 蔡晓鹏 | Rubus chingii decoction piece and preparation method thereof |
| CN103284143B (en) * | 2012-03-31 | 2014-10-08 | 蔡晓鹏 | Rubus chingii decoction piece and preparation method thereof |
| CN102987548A (en) * | 2012-12-05 | 2013-03-27 | 陕西中烟工业有限责任公司 | Plant extract capable of reducing harmful substances in cigarette and preparation method thereof |
| CN102987548B (en) * | 2012-12-05 | 2014-09-17 | 陕西中烟工业有限责任公司 | Plant extract capable of reducing harmful substances in cigarette and preparation method thereof |
| CN103316024A (en) * | 2013-06-18 | 2013-09-25 | 中国人民解放军第二军医大学 | Application of labdane diterpene glycoside compounds in rubus chingii Hu as medicine |
| CN103316024B (en) * | 2013-06-18 | 2015-03-04 | 中国人民解放军第二军医大学 | Application of labdane diterpene glycoside compounds in rubus chingii Hu as medicine |
| CN103623082A (en) * | 2013-11-29 | 2014-03-12 | 江西中医药大学 | Raspberry extract and application thereof |
| CN103623082B (en) * | 2013-11-29 | 2016-08-17 | 江西中医药大学 | Fructus Rubi extract and application thereof |
| CN107353273A (en) * | 2017-07-17 | 2017-11-17 | 湖南楚宏生物科技有限公司 | The method that cyanidenon and Rubus corchorifolius element are extracted from Rubus corchorifolius |
| CN107353273B (en) * | 2017-07-17 | 2019-12-03 | 抚州市东乡区九鼎牧业有限公司 | The method of luteolin and Rubus corchorifolius element is extracted from Rubus corchorifolius |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101732440B (en) | 2012-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101732440B (en) | Raspberry extract and raspberry element obtain by separation thereof and application thereof | |
| CN115154476B (en) | Cyclocarya paliurus extract and application thereof in resisting gout and reducing uric acid | |
| CN103316024B (en) | Application of labdane diterpene glycoside compounds in rubus chingii Hu as medicine | |
| CN103405487B (en) | Chinese medicine compound effective part with effect of treating arthritis | |
| CN107011453A (en) | One kind dimension medicine just ancient polysaccharide of fiber crops and its extracting method and application | |
| Xue-Ying et al. | Regulatory effects of Poria on substance and energy metabolism in cold-deficiency syndrome compared with heat-deficiency syndrome in rats | |
| CN101480419B (en) | Polysaccharide extract of Periploca forrestii Schltr, and preparation method thereof | |
| Jin et al. | Study the mechanism of peimisine derivatives on NF‐κB inflammation pathway on mice with acute lung injury induced by lipopolysaccharide | |
| CN106008485A (en) | Medicinal composition of glimepiride, and application thereof in biomedicines | |
| CN108619316A (en) | Active component of matrimony vine young tea leaves and preparation method thereof, application | |
| CN102727558A (en) | Tripterygium Hypoglaucum Hutch root extract, and bi-layer extended release tablet and application thereof | |
| CN112876469B (en) | Lupine derivative with effects of relieving cough and reducing phlegm and preparation method thereof | |
| CN104257756B (en) | The application in preparing hypoglycemic medicine of a kind of Cortex Mori fatty oil | |
| WO2005084689A1 (en) | Radix astragli extract and production method and use thereof | |
| CN113827629A (en) | Application of folium Artemisiae Argyi in treating and preventing stomach diseases caused by helicobacter pylori | |
| CN105884841B (en) | A kind of preparation method of phenylpropanoids | |
| CN105859738A (en) | Hydralazine hydrochloride medicine composition and medical application thereof | |
| CN105732736B (en) | A kind of preparation method of phenylpropanoids | |
| CN105708845B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN108997473A (en) | A kind of non-sea cucumber alkane type selenka and the preparation method and application thereof | |
| CN106046071B (en) | A kind of preparation method of phenylpropanoids | |
| CN112898358B (en) | New compound NBY-4 extracted from folium Arctii and having antiinflammatory activity, and its preparation method and application | |
| CN109081842A (en) | A kind of deep-sea originated from fungus anthraquinone analog compound and its preparing the application in Claritin | |
| CN105601681B (en) | A kind of preparation method of phenylpropanoids | |
| CN109705077B (en) | Coumarin compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20141215 |
|
| EXPY | Termination of patent right or utility model |